Evolocumab
Evolocumab
Definition
A human immunoglobulin G2 (IgG2) monoclonal antibody directed against human proprotein convertase subtilisin/kexin type 9 (PCSK9), that can be used in the treatment of hypercholesterolemia. Upon administration, evolocumab targets, binds to and inhibits the activity of PCSK9. This prevents binding of PCSK9 to low-density lipoprotein receptor (LDLR) on hepatocytes and prevents its degradation. This increases LDLR on hepatocytes and increases the liver's ability to remove LDL cholesterol (LDL-C) from the blood, thereby lowering LDL-C levels. PCSK9 binds to LDLR on the surface of hepatocytes to promote LDLR degradation within the liver.
Also known as AMG 145, AMG-145, AMG145, EVOLOCUMAB, Repatha — per NCIT
Also identified as
- ATC C10AX13 per RXNORM
- NCIT NCIT:C174672 per NCIT
- SCTID 716068004 per RXNORM
- SCTID 763586000 per RXNORM
- UNII LKC0U3A8NJ per RXNORM
Indications
| Disease | Relation | Source |
|---|---|---|
| Atherosclerosis | may prevent | MEDRT · Public domain (U.S. Government work) |
| Myocardial infarction | may prevent | MEDRT · Public domain (U.S. Government work) |
| Atherosclerosis | may treat | MEDRT · Public domain (U.S. Government work) |
Organ Effects
| Organ | Side effect / interaction | Source |
|---|---|---|
| Artery | may treat a disease of this organ | DERIVED · CC BY 4.0 |
| Cardiovascular system | may treat a disease of this organ | DERIVED · CC BY 4.0 |
2 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.